Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.62 |
| ▸ | NPC1 | O15118 | 7/20 | 0.57 |
| ▸ | RAB9A | P51151 | 7/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.57 |
| ▸ | HPGD | P15428 | 5/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.57 |
| ▸ | TSHR | P16473 | 4/20 | 0.57 |
| ▸ | PKM | P14618 | 3/20 | 0.57 |
| ▸ | TP53 | P04637 | 3/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.57 |
| ▸ | MAPT | P10636 | 4/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.52 |
| ▸ | RELA | Q04206 | 1/20 | 0.52 |
| ▸ | DRD2 | P14416 | 2/20 | 0.50 |
| ▸ | DRD3 | P35462 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12797279 | 0.89 | SMN1; SMN2 (0.54) | HRH3NPC1RAB9AKDM4EHPGD | |
| SCHEMBL6388711 | 0.88 | RAB9A (0.74) | HRH3NPC1RAB9AKDM4EHPGD | |
| SCHEMBL12848495 | 0.87 | RAB9A (0.70) | HRH3NPC1RAB9AKDM4EHPGD | |
| SCHEMBL12848607 | 0.86 | ALDH1A1 (0.53) | HRH3NPC1RAB9AKDM4EHPGD | |
| SCHEMBL12848990 | 0.86 | NPC1 (0.53) | HRH3NPC1RAB9AKDM4EHPGD | |
| SCHEMBL12848976 | 0.85 | RAB9A (0.69) | HRH3NPC1RAB9AKDM4EHPGD | |
| SCHEMBL6390132 | 0.85 | RAB9A (0.71) | HRH3NPC1RAB9AKDM4EHPGD | |
| SCHEMBL12848935 | 0.85 | ALDH1A3 (0.58) | NPC1RAB9AKDM4EHPGDALDH1A1 | |
| SCHEMBL9284193 | 0.84 | RAB9A (0.74) | HRH3NPC1RAB9AKDM4EHPGD | |
| SCHEMBL12848993 | 0.83 | RAB9A (0.55) | HRH3NPC1RAB9AKDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1381363-B1 | IMIDAZO [1,2-A]-PYRIDINE DERIVATIVES AS MGLUR5 ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2004-12-08 | — | — | EP | claimed |
| US-8895599-B2 | Lipoprotein lipase-activating compositions comprising benzene derivates | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 2014-11-25 | — | — | US | disclosed |
| US-20130296342-A1 | LIPOPROTEIN LIPASE-ACTIVATING COMPOSITIONS COMPRISING BENZENE DERIVATES | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 2013-11-07 | — | — | US | disclosed |
| US-20110065728-A1 | LIPOPROTEIN LIPASE-ACTIVATING COMPOSITIONS COMPRISING BENZENE DERIVATIVES | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 2011-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130296342-A1 | LIPOPROTEIN LIPASE-ACTIVATING COMPOSITIONS COMPRISING BENZENE DERIVATES | LPL, LIPC, LIPE | HRH3 2016/4885NPC1 366/4885RAB9A 3933/4885 |
| US-20110065728-A1 | LIPOPROTEIN LIPASE-ACTIVATING COMPOSITIONS COMPRISING BENZENE DERIVATIVES | LPL, LIPC, LIPE | HRH3 1936/4885NPC1 334/4885RAB9A 3849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.